A recent double-blind phase 3 clinical study recruiting 907 locally advanced HNSCC patients showed that concurrent use of anti-PD-L1 avelumab with chemoradiotherapy did not prolong progression-free survival compared to patients who received placebo with chemoradiotherapy (NCT02952586 ) [17]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.